Skip to main content
SpringerLink
Log in

Vorhofflimmern

Neue Antiarrhythmika und Antikoagulanzien

Atrial fibrillation

New anticoagulants and antiarrhythmic drugs

  • Schwerpunkt
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Vorhofflimmern ist die häufigste Herzrhythmusstörung im Alter und eine Hauptursache des ischämischen Schlaganfalls. Zur Schlaganfallprophylaxe sind zuletzt mehrere neue Antikoagulanzien als Alternative zu Vitamin-K-Antagonisten entwickelt und in Phase-3-Studien hinsichtlich Effektivität und Sicherheit untersucht worden. Entscheidend für die klinische Anwendung der neuen Substanzen ist die Identifizierung von Patienten, die vom Einsatz der neuen Substanzen besonders profitieren. Zur Rhythmuskontrolle von Vorhofflimmern gibt es mit Vernakalant und Dronedaron ebenfalls zwei neue Substanzen, deren Effektivität im Vergleich zur etablierten Therapie jedoch noch nachhaltig nachgewiesen werden muss.

Abstract

Atrial fibrillation is the most common form of arrhythmia and one of the most frequent causes of ischemic stroke. Several new anticoagulants have recently been introduced as alternatives to vitamin-K antagonists for prophylaxis of ischemic stroke and tested in phase-3 studies for efficacy and safety. Identifying patients who will profit in particular from the new anticoagulant therapy is crucial to the clinical application of these drugs. Vernakalant and dronedarone are new antiarrhythmic drugs for rhythm control of atrial fibrillation. However, therapeutic efficacy of the new agents still has to be proven.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 285:2370–2375

    Article  PubMed  CAS  Google Scholar 

  2. Kaarisalo MM, Immonen-Raiha P, Marttila RJ et al (1997) Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke 28:311–315

    Article  PubMed  CAS  Google Scholar 

  3. Marini C, De Santis F, Sacco S et al (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36:1115–1119

    Article  PubMed  Google Scholar 

  4. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429

    Article  PubMed  Google Scholar 

  5. Shin DI, Eckardt L (2011) New concepts in the therapy of atrial fibrillation. Dtsch Med Wochenschr 136:1587–1590

    Article  PubMed  Google Scholar 

  6. Wasmer K, Eckardt L (2011) Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace 13:1368–1374

    Article  PubMed  Google Scholar 

  7. Gladstone DJ, Bui E, Fang J et al (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235–240

    Article  PubMed  CAS  Google Scholar 

  8. Hoffman M, Monroe DM 3rd (2001) A cell-based model of hemostasis. Thromb Haemost 85(6):958–965

    PubMed  CAS  Google Scholar 

  9. Weitz JI, Bates SM (2005) New anticoagulants. J Thromb Haemost 3(8):1843–1853

    Article  PubMed  CAS  Google Scholar 

  10. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  PubMed  CAS  Google Scholar 

  11. Eikelboom JW, Wallentin L, Connolly SJ et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial. Circulation 123:2363–2372

    Article  PubMed  CAS  Google Scholar 

  12. Lopes RD, Alexander JH, Al-Khatib SM et al (2010) Apixaban for reduction in rtroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159:331–339

    Article  PubMed  CAS  Google Scholar 

  13. ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159:340–347 e341

    Article  Google Scholar 

  14. Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833

    Article  PubMed  CAS  Google Scholar 

  15. Connolly SJ, Crijns HJ, Torp-Pedersen C et al (2009) Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 120:1174–1180

    Article  PubMed  CAS  Google Scholar 

  16. Connolly SJ, Camm AJ, Halperin JL et al (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365(24):2268–2276

    Article  PubMed  CAS  Google Scholar 

  17. Roy D, Pratt CM, Torp-Pedersen C et al (2008) Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117:1518–1525

    Article  PubMed  CAS  Google Scholar 

  18. Pratt CM, Roy D, Torp-Pedersen C et al (2010) Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 106:1277–1283

    Article  PubMed  CAS  Google Scholar 

  19. Kowey PR, Dorian P, Mitchell LB et al (2009) Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2:652–659

    Article  PubMed  Google Scholar 

  20. Stiell IG, Roos JS, Kavanagh KM (2010) A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 159:1095–1101

    Article  PubMed  CAS  Google Scholar 

  21. Camm AJ, Capucci A, Hohnloser SH et al (2011) A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 57:313–321

    Article  PubMed  Google Scholar 

  22. Torp-Pedersen C, Raev DH, Dickinson G et al (2011) A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol 4:637–643

    Article  PubMed  CAS  Google Scholar 

  23. Torp-Pedersen C, Camm AJ, Butterfield NN et al (2011) Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol [Epub ahead of print]

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Abteilung für Rhythmologie, Department für Kardiologie und Angiologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Deutschland

    E. Kaya#, G. Frommeyer#, G. Mönnig & L. Eckardt

Authors
  1. E. Kaya#
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Frommeyer#
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Mönnig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Eckardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Kaya#.

Additional information

# both authors contributed equally

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaya#, E., Frommeyer#, G., Mönnig, G. et al. Vorhofflimmern. Herz 37, 159–165 (2012). https://doi.org/10.1007/s00059-012-3589-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-012-3589-x

Schlüsselwörter

Keywords

Search

Navigation